SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Instagram Outage Disrupts Thousands of U.S. Users 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
NEWARK, Calif., Feb. 07, 2018 --
Depomed, Inc. (NASDAQ:DEPO) today announced that members of senior management will participate in fireside chats at the following healthcare conferences during the month of February.
LEERINK Partners 7th Annual Global Healthcare Conference
Date: Wednesday, February 14, 2018
Time: 2:00 p.m. EST
Location: New York, New York
RBC Capital Markets 2018 Global Healthcare Conference
Date: Thursday, February 22, 2018
Time: 11:30 a.m. EST
Location: New York, New York
The fireside chats will be webcast live and may be accessed via the Investor Relations’ page of the Depomed website at www.depomed.com. A recording of these events will be archived for 30 days on the company's website.
About Depomed
Depomed is a leading specialty pharmaceutical company committed to putting the Patient First in everything it does. Depomed is focused on enhancing the lives of patients, families, physicians, providers and payors through the commercialization of products in the areas of pain and neurology, and in the development of drugs in areas of unmet medical need. Depomed currently markets three medicines focused on neuropathic pain and migraine through its Neurology and Pain businesses and its emerging Specialty Business is focused on orphan drug indications and areas of unmet medical need. To learn more about Depomed, visit www.depomed.com.
Investor Contact:
Christopher Keenan
VP, Investor Relations and Corporate Communications
510-744-8000
[email protected]
